Logo

PhoreMost Signs a Multi-Project Drug Discovery Agreement with Boehringer Ingelheim

Share this

PhoreMost Signs a Multi-Project Drug Discovery Agreement with Boehringer Ingelheim

Shots:

  • PhoreMost to receive upfront and research funding plus milestones and will utilize its expertise and phenotypic screening platform- SITESEEKER for the targets identified by BI and will be further included in and validated in BI’s pipeline
  • The focus of the agreement is to enhance BI’s drug discovery pipeline utilizing PhoreMost’s PROTEINi and SITESEEKER platform to identify novel targets for multiple diseases
  • SITESEEKER platform is based on PROTEINi technology enables the inception of novel drug discovery programs. PROTEINi are small fragments of larger proteins broken into small subunits retaining a 3D structure find a diversity of new 3D binding sites across the entire proteome

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Behance


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions